Synopsis:
EGFR and ALK mutations are seen simultaneously very rarely. We believe that EGFR-TKI can be used to EGFR (except exon 20 insertions or T790M mutation) and ALK dual mutant patients as the first treatment. Examination of ROS1 mutation must be used as an indicator in the chose of the crizotinib treatment. Also, we believe that combined use of EGFR-TKI and ALK-TKI would at least increase the chance of success in patients with dual mutant.